相似文献
1
Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.
Expert Opin Investig Drugs. 2010 Feb;19(2):275-83. doi: 10.1517/13543780903501539.
2
Pirfenidone in idiopathic pulmonary fibrosis.
Drugs Today (Barc). 2010 Jul;46(7):473-82. doi: 10.1358/dot.2010.46.7.1488336.
3
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.
4
Role and New Insights of Pirfenidone in Fibrotic Diseases.
Int J Med Sci. 2015 Oct 14;12(11):840-7. doi: 10.7150/ijms.11579. eCollection 2015.
5
Pirfenidone use in fibrotic diseases: What do we know so far?
Immun Inflamm Dis. 2024 Jul;12(7):e1335. doi: 10.1002/iid3.1335.
6
Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Expert Opin Pharmacother. 2014 Feb;15(2):275-81. doi: 10.1517/14656566.2014.867328. Epub 2013 Dec 6.
7
Pirfenidone.
IDrugs. 2004 Feb;7(2):166-72.
8
A safety evaluation of pirfenidone for the treatment of idiopathic pulmonary fibrosis.
Expert Opin Drug Saf. 2016 Jul;15(7):975-82. doi: 10.1080/14740338.2016.1187129. Epub 2016 May 26.
9
Pirfenidone is a renal protective drug: Mechanisms, signalling pathways, and preclinical evidence.
Eur J Pharmacol. 2021 Nov 15;911:174503. doi: 10.1016/j.ejphar.2021.174503. Epub 2021 Sep 20.
10
Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model.
Biochem Pharmacol. 2016 Oct 1;117:57-67. doi: 10.1016/j.bcp.2016.08.002. Epub 2016 Aug 4.
引用本文的文献
1
Postoperative Adhesions: Current Research on Mechanisms, Therapeutics and Preventative Measures.
Biomed Mater Devices. 2025 Sep;3(2):897-937. doi: 10.1007/s44174-024-00236-7. Epub 2024 Sep 17.
2
Exploring the potential of herbal drugs for treating liver fibrosis: a computational screening approach.
Asian Biomed (Res Rev News). 2025 Apr 30;19(2):78-85. doi: 10.2478/abm-2025-0010. eCollection 2025 Apr.
3
Lead-Induced Nephrotoxicity and Its Therapeutic Interventions: An Updated Review.
Biol Trace Elem Res. 2025 Jun 13. doi: 10.1007/s12011-025-04692-0.
4
Pirfenidone as a Cornerstone in the Management of Fibrotic Interstitial Lung Diseases and Its Emerging Applications: A Comprehensive Review.
Cureus. 2024 Sep 30;16(9):e70497. doi: 10.7759/cureus.70497. eCollection 2024 Sep.
5
Pirfenidone use in fibrotic diseases: What do we know so far?
Immun Inflamm Dis. 2024 Jul;12(7):e1335. doi: 10.1002/iid3.1335.
6
Fibrosis in Chronic Kidney Disease: Pathophysiology and Therapeutic Targets.
J Clin Med. 2024 Mar 25;13(7):1881. doi: 10.3390/jcm13071881.
7
Evaluation of prevention and treatment effects of fibroblast growth factor-21 in BLM-induced pulmonary fibrosis.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Nov;396(11):3299-3313. doi: 10.1007/s00210-023-02540-3. Epub 2023 May 31.
8
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis.
Life (Basel). 2023 Feb 10;13(2):486. doi: 10.3390/life13020486.
9
Phenotypic screening of 1,953 FDA-approved drugs reveals 26 hits with potential for repurposing for Peyronie's disease.
PLoS One. 2022 Dec 12;17(12):e0277646. doi: 10.1371/journal.pone.0277646. eCollection 2022.
10
New Drugs for Hepatic Fibrosis.
Front Pharmacol. 2022 Jun 13;13:874408. doi: 10.3389/fphar.2022.874408. eCollection 2022.
本文引用的文献
1
Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.
Transplantation. 2009 Aug 15;88(3):330-8. doi: 10.1097/TP.0b013e3181ae3392.
2
Pirfenidone is renoprotective in diabetic kidney disease.
J Am Soc Nephrol. 2009 Aug;20(8):1765-75. doi: 10.1681/ASN.2008090931. Epub 2009 Jul 2.
3
Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.
Pulm Pharmacol Ther. 2009 Aug;22(4):279-85. doi: 10.1016/j.pupt.2009.03.003. Epub 2009 Mar 27.
4
Overview of factors contributing to the pathophysiology of progressive renal disease.
Kidney Int. 2008 Oct;74(7):860-6. doi: 10.1038/ki.2008.351. Epub 2008 Jul 23.
5
Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.
Life Sci. 2008 Jan 16;82(3-4):210-7. doi: 10.1016/j.lfs.2007.11.003. Epub 2007 Nov 23.
6
Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers.
J Clin Pharmacol. 2007 Oct;47(10):1268-76. doi: 10.1177/0091270007304104.
7
Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.
Transplant Proc. 2007 Sep;39(7):2153-6. doi: 10.1016/j.transproceed.2007.07.078.
8
Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.
Clin J Am Soc Nephrol. 2007 Sep;2(5):906-13. doi: 10.2215/CJN.01050207. Epub 2007 Aug 16.
9
Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.
Radiat Oncol. 2007 May 31;2:19. doi: 10.1186/1748-717X-2-19.
10
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
Pediatr Neurol. 2007 May;36(5):293-300. doi: 10.1016/j.pediatrneurol.2007.01.009.
Zotero 插件